Novartis invests in early technical growth capabilities for next-generation biotherapeutics

Novartis invests in early technical growth capabilities for next-generation biotherapeutics

  • Multi-year funding of USD 300m will create built-in scientific surroundings to ship on growing development and variety of biotherapeutics portfolio  
  • Enhanced capability and processes anticipated to result in quicker transition occasions from pre-clinical to first-in-human research
  • Dedication to early section biologics growth in Switzerland, Slovenia & Austria

Basel, Sept 12, 2022 — Novartis immediately introduced it’s investing in next-generation biotherapeutics with the creation of a totally built-in, devoted USD 300m scientific surroundings that may bolster its capability and capabilities for early technical growth of biologics. Spanning each drug substance and drug product growth, the multi-year funding shall be carried out throughout present Novartis places in Switzerland, Slovenia and Austria, strengthening Novartis means to ship on the growing development and variety of its early-stage biotherapeutics portfolio.

“Throughout the trade, biotherapeutics account for nearly one-half of all latest new drug approvals and have huge potential to deal with unmet want throughout a variety of illnesses,” stated Reto Fischer, Head of Technical Analysis Division, World Drug Improvement (GDD), Novartis. “We’re constructing the scientific surroundings essential to carry these advanced biologic compounds from the bench by way of growth in an built-in, seamless, and fast vogue. In doing so, we’re supporting our broader ambition to allow quicker growth and centered prioritization throughout our world portfolio.”

The Novartis early-stage biologics portfolio has grown considerably within the final 15 years. It has additionally expanded past standard monoclonal antibodies into a variety of novel growth candidates with potential to be first-in-class, best-in-class, or each, together with antibody-drug conjugates and therapeutic proteins.

This funding is meant to place Novartis on the forefront of biotherapeutic growth, by supporting the corporate’s more and more subtle pipeline with essentially the most superior technical infrastructure, alongside the very best degree of capabilities. It’ll create seamless, end-to-end growth and manufacturing environments by embedding biologics growth inside present Novartis business manufacturing services in Slovenia and Austria in addition to by establishing a biologic’s hub on the Basel St. Johann Campus in Switzerland alongside the NIBR biologics middle fostering scientific innovation, know-how management and expertise attraction. Collectively these commitments will improve growth processes concentrating on quicker transition occasions from pre-clinical to first in human research.

Particularly, the funding will:

  • Strengthen the Novartis St. Johann campus in Basel by investing USD 100M to determine a biologics hub to enrich the present NIBR Biologics Middle; 
  • Create a biocampus in Mengeš, Slovenia with an funding of USD 110M in scientific manufacturing capabilities (non cGMP and cGMP) and technical growth capabilities in proximity of growth operations; and
  • Amplify synergies and strategic proximity on the Schaftenau campus in Austria with a USD 60M USD funding in growth manufacturing capability and capabilities.

“The science of creating biologics is more and more subtle, and we’re excited to fulfill its challenges head-on,” stated Jonathan Novak, World Head for Biologics, Technical Analysis Division, GDD at Novartis. “We look ahead to amplifying the data and expertise of our associates to make sure that biologics growth is an exhilarating and rewarding course of for our present and future colleagues – and that’s finally a supply of profoundly revolutionary new therapies for sufferers worldwide.”

Disclaimer
This media replace comprises forward-looking statements throughout the that means of the US Personal Securities Litigation Reform Act of 1995. Ahead-looking statements can typically be recognized by phrases corresponding to “potential,” “can,” “will,” “plan,” “might,” “might,” “would,” “count on,” “anticipate,” “look ahead,” “imagine,” “dedicated,” “investigational,” “pipeline,” “launch,” or related phrases, or by specific or implied discussions relating to potential advertising approvals, new indications or labeling for the investigational or authorized merchandise described on this media replace, or relating to potential future revenues from such merchandise. You shouldn’t place undue reliance on these statements. Such forward-looking statements are primarily based on our present beliefs and expectations relating to future occasions, and are topic to vital identified and unknown dangers and uncertainties. Ought to a number of of those dangers or uncertainties materialize, or ought to underlying assumptions show incorrect, precise outcomes might fluctuate materially from these set forth within the forward-looking statements. There might be no assure that the investigational or authorized merchandise described on this media replace shall be submitted or authorized on the market or for any further indications or labeling in any market, or at any specific time. Nor can there be any assure that such merchandise shall be commercially profitable sooner or later. Particularly, our expectations relating to such merchandise might be affected by, amongst different issues, the uncertainties inherent in analysis and growth, together with scientific trial outcomes and extra evaluation of present scientific information; regulatory actions or delays or authorities regulation typically; world tendencies towards well being care price containment, together with authorities, payor and normal public pricing and reimbursement pressures and necessities for elevated pricing transparency; our means to acquire or keep proprietary mental property safety; the actual prescribing preferences of physicians and sufferers; normal political, financial and enterprise circumstances, together with the consequences of and efforts to mitigate pandemic illnesses corresponding to COVID-19; security, high quality, information integrity or manufacturing points; potential or precise information safety and information privateness breaches, or disruptions of our info know-how methods, and different dangers and elements referred to in Novartis AG’s present Kind 20-F on file with the US Securities and Alternate Fee. Novartis is offering the data on this media replace as of this date and doesn’t undertake any obligation to replace any forward-looking statements contained on this media replace because of new info, future occasions or in any other case.

About Novartis
Novartis is reimagining medication to enhance and prolong individuals’s lives. As a number one world medicines firm, we use revolutionary science and digital applied sciences to create transformative therapies in areas of nice medical want. In our quest to seek out new medicines, we constantly rank among the many world’s high corporations investing in analysis and growth. Novartis merchandise attain almost 800 million individuals globally and we’re discovering revolutionary methods to broaden entry to our newest therapies. About 108,000 individuals of greater than 140 nationalities work at Novartis around the globe. Discover out extra at https://www.novartis.com.

Novartis is on Twitter. Signal as much as observe @Novartis at https://twitter.com/novartisnews 
For Novartis multimedia content material, please go to https://www.novartis.com/information/media-library 
For questions in regards to the web site or required registration, please contact [email protected] 

# # #

Novartis Media Relations
E-mail: [email protected] 

Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: [email protected] 

Central   North America  
Samir Shah +41 61 324 7944 Sloan Simpson +1 862 345 4440
Nicole Zinsli-Somm +41 61 324 3809 Alina Levchuk +1 862 778 3372
Isabella Zinck +41 61 324 7188 Parag Mahanti +1 973-876-4912

Novartis invests in early technical growth capabilities for next-generation biotherapeutics

Leave a Reply